WO2008038302A3 - Therapeutic formulation comprising a sulfonylurea, metformin and a nitric oxide scavenger. - Google Patents

Therapeutic formulation comprising a sulfonylurea, metformin and a nitric oxide scavenger. Download PDF

Info

Publication number
WO2008038302A3
WO2008038302A3 PCT/IN2007/000434 IN2007000434W WO2008038302A3 WO 2008038302 A3 WO2008038302 A3 WO 2008038302A3 IN 2007000434 W IN2007000434 W IN 2007000434W WO 2008038302 A3 WO2008038302 A3 WO 2008038302A3
Authority
WO
WIPO (PCT)
Prior art keywords
metformin
therapeutic formulation
sulfonylurea
nitric oxide
oxide scavenger
Prior art date
Application number
PCT/IN2007/000434
Other languages
French (fr)
Other versions
WO2008038302A2 (en
Inventor
Jegannathan Srinivas
Original Assignee
Jegannathan Srinivas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jegannathan Srinivas filed Critical Jegannathan Srinivas
Publication of WO2008038302A2 publication Critical patent/WO2008038302A2/en
Publication of WO2008038302A3 publication Critical patent/WO2008038302A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/38—Silver; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A therapeutic formulation comprising of Sulfonylureas as active agents namely, Glibenclamide, Gliclazide, Glimepiride, Glipizide and Gliquidone, characterized in that said Sulfonylureas are combined with Metformin and combined or complexated with NO Scavenger to prevent Diabetic Complications arising out of Nitrosative stress.
PCT/IN2007/000434 2006-09-26 2007-09-26 Therapeutic formulation comprising a sulfonylurea, metformin and a nitric oxide scavenger. WO2008038302A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1759/CHE/2006 2006-09-26
IN1759CH2006 2006-09-26

Publications (2)

Publication Number Publication Date
WO2008038302A2 WO2008038302A2 (en) 2008-04-03
WO2008038302A3 true WO2008038302A3 (en) 2008-05-29

Family

ID=39230686

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2007/000434 WO2008038302A2 (en) 2006-09-26 2007-09-26 Therapeutic formulation comprising a sulfonylurea, metformin and a nitric oxide scavenger.

Country Status (1)

Country Link
WO (1) WO2008038302A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3253485B1 (en) * 2015-02-03 2021-12-15 University Court of The University of St Andrews No containing compositions

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997032585A1 (en) * 1996-03-05 1997-09-12 Medinox, Inc. Combinational therapeutic methods employing nitric oxide scavengers and compositions useful therefor
WO1998011066A1 (en) * 1996-09-10 1998-03-19 Medinox, Inc. Polydithiocarbamate-containing macromolecules and the use thereof for therapeutic and diagnostic applications
WO1999066924A1 (en) * 1998-06-23 1999-12-29 Medinox, Inc. Use of nitric oxide scavengers to treat side effects caused by therapeutic administration of sources of nitric oxide
US20020151540A1 (en) * 2000-05-05 2002-10-17 Medinox, Inc. Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor
WO2005027981A1 (en) * 2003-09-17 2005-03-31 Board Of Regents, The University Of Texas System Mechanism-based targeted pancreatic beta cell imaging and therapy

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997032585A1 (en) * 1996-03-05 1997-09-12 Medinox, Inc. Combinational therapeutic methods employing nitric oxide scavengers and compositions useful therefor
WO1998011066A1 (en) * 1996-09-10 1998-03-19 Medinox, Inc. Polydithiocarbamate-containing macromolecules and the use thereof for therapeutic and diagnostic applications
WO1999066924A1 (en) * 1998-06-23 1999-12-29 Medinox, Inc. Use of nitric oxide scavengers to treat side effects caused by therapeutic administration of sources of nitric oxide
US20020151540A1 (en) * 2000-05-05 2002-10-17 Medinox, Inc. Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor
WO2005027981A1 (en) * 2003-09-17 2005-03-31 Board Of Regents, The University Of Texas System Mechanism-based targeted pancreatic beta cell imaging and therapy

Also Published As

Publication number Publication date
WO2008038302A2 (en) 2008-04-03

Similar Documents

Publication Publication Date Title
WO2008062273A3 (en) Solid oral dosage form having antidiabetic drug combination
PH12019500959B1 (en) Combinations of sglt 2 inhibitors and antidiabetic agents
WO2008060963A3 (en) Layered pharmaceutical formulations comprising an intermediate rapidly dissolving layer
EP1935418A4 (en) Composition for relieving subjective symptoms of fatigue
WO2003026637A3 (en) Dosage form for treatment of diabetes mellitus
HK1087009A1 (en) Medicament comprising a highly potent long-lastingbeta2-agonist in combination with other active in gredients
NZ605538A (en) Synergistic insecticidal mixtures
WO2007002597A3 (en) Modified-release formulations of a bupropion salt
WO2008005411A3 (en) Resecting device
EP2070509A3 (en) The use of Myrica gale oil
UA91852C2 (en) Pharmaceutical formulation containing a metformin and a pioglitazone as active medicaments
WO2005103002A3 (en) Novel alkyne compounds with an mch-antagonistic action and medicaments comprising said compounds
WO2007007095A3 (en) Pharmaceutical compositions comprising a tgf-beta superfamily member
EP1852114A4 (en) COMPOSITION CONTAINING DIHOMO-(gamma)-LINOLENIC ACID (DGLA) AS THE ACTIVE INGREDIENT
MXPA05013667A (en) Dual component skin care compositions that comprise a self-tanning agent.
WO2005117913A3 (en) Ozonized pharmaceutical composition and method
WO2008038302A3 (en) Therapeutic formulation comprising a sulfonylurea, metformin and a nitric oxide scavenger.
WO2009019176A3 (en) Fungicidal mixtures
WO2008038303A3 (en) Therapeutic formulation comprising a sulfonylurea, a thiazolidinedione and a nitric oxide scavenger.
WO2008014256A3 (en) Composition including superoxide dismutase and prickly-pear cactus for minimizing and preventing hangovers
WO2008082948A3 (en) Ophthalmic alginate composition related methods of manufacture and methods of use
WO2006102004A3 (en) A stable aqueous-based emulsion formulation comprising urea and salicylic acid and method of using same
BRPI0613447A2 (en) pharmaceutical composition, uses of a ppargam agonist and a biguanide agent, and kit to prevent adverse side effects due to the action of a biguanide agent in the treatment of diabetes
EP1629852A3 (en) Topical anaesthesia formulation for bodily cavities
WO2006117404A3 (en) Topical use of radical capturing substances for antipyretic treatment

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07827583

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC DATED 18-09-2009

122 Ep: pct application non-entry in european phase

Ref document number: 07827583

Country of ref document: EP

Kind code of ref document: A2